InterPAD - DETAILS

ERASTIN, 571203-78-6, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone, 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, MFCD09837984, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-1-piperazinyl)ethyl)-3-(2-ethoxyphenyl)-4(3H)-quinazolinone, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4-one, 2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-quinazolinone;, ZJA3NS42T9, CHEMBL401989, SCHEMBL4457820, Erastin, >=98% (HPLC), CHEBI:94287, DTXSID80458949, EX-A295, HMS3653K21, HMS3868M03, BCP27907, WXA20378, BDBM50376126, s7242, AKOS025147365, CCG-269987, CS-1675, Erastin - CAS 571203-78-6, SB19588, NCGC00351608-10, NCGC00351608-14, AC-35446, AS-55898, DA-42059, HY-15763, SY345515, E7781, FT-0700333, SW208651-2, C21478, E-7781, A869751, BRD-A25004090-001-01-9, BRD-A25004090-001-02-7, BRD-A25004090-001-06-8, Q27166099, 2-[1-[4-[2-(4-chlorophenoxy)-1-oxoethyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4-quinazolinone, 2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, 4(3H)-Quinazolinone, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-, Piperazine, 1-((4-chlorophenoxy)acetyl)-4-(1-(3-(2-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl)-

No.	Title	Href
1	Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. Oxid Med Cell Longev. 2022 Jul 19;2022:5361241. doi: 10.1155/2022/5361241.	`Click`
2	Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression. Free Radic Biol Med. 2023 Nov 1;208:530-544. doi: 10.1016/j.freeradbiomed.2023.09.014.	`Click`
3	Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation. Toxicol In Vitro. 2024 Feb;94:105732. doi: 10.1016/j.tiv.2023.105732.	`Click`

No.

Title

Href

Vitamin C Sensitizes Pancreatic Cancer Cells to Erastin-Induced Ferroptosis by Activating the AMPK/Nrf2/HMOX1 Pathway. Oxid Med Cell Longev. 2022 Jul 19;2022:5361241. doi: 10.1155/2022/5361241.

Click

Luteolin exhibits synergistic therapeutic efficacy with erastin to induce ferroptosis in colon cancer cells through the HIC1-mediated inhibition of GPX4 expression. Free Radic Biol Med. 2023 Nov 1;208:530-544. doi: 10.1016/j.freeradbiomed.2023.09.014.

Click

Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation. Toxicol In Vitro. 2024 Feb;94:105732. doi: 10.1016/j.tiv.2023.105732.

Click

Name	Erastin
PubChem CID	11214940
Molecular Weight	547.0g/mol
Synonyms	ERASTIN, 571203-78-6, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone, 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, MFCD09837984, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-1-piperazinyl)ethyl)-3-(2-ethoxyphenyl)-4(3H)-quinazolinone, 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4-one, 2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-quinazolinone;, ZJA3NS42T9, CHEMBL401989, SCHEMBL4457820, Erastin, >=98% (HPLC), CHEBI:94287, DTXSID80458949, EX-A295, HMS3653K21, HMS3868M03, BCP27907, WXA20378, BDBM50376126, s7242, AKOS025147365, CCG-269987, CS-1675, Erastin - CAS 571203-78-6, SB19588, NCGC00351608-10, NCGC00351608-14, AC-35446, AS-55898, DA-42059, HY-15763, SY345515, E7781, FT-0700333, SW208651-2, C21478, E-7781, A869751, BRD-A25004090-001-01-9, BRD-A25004090-001-02-7, BRD-A25004090-001-06-8, Q27166099, 2-[1-[4-[2-(4-chlorophenoxy)-1-oxoethyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4-quinazolinone, 2-[1-[4-[2-(4-Chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4(3H)-one, 4(3H)-Quinazolinone, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-, Piperazine, 1-((4-chlorophenoxy)acetyl)-4-(1-(3-(2-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl)-
Drug Type	Small molecule
Formula	C₃₀H₃₁ClN₄O₄
SMILES	CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl
InChI	1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3
InChIKey	BKQFRNYHFIQEKN-UHFFFAOYSA-N
CAS Number	571203-78-6
ChEMBL ID	CHEMBL401989
ChEBI ID	CHEBI:94287
KEGG ID	C21478
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Vitamin C, Erastin
Partner Name	Vitamin C
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	CP	hsa1356
	Up-regulation	Expression	HMOX1	hsa3162
	Up-regulation	Expression	NCOA4	hsa8031
	Up-regulation	Expression	NFE2L2	hsa4780
	Up-regulation	Expression	NFE2L2	hsa4780
	Up-regulation	Phosphorylation	PRKAA1	hsa5562
	Up-regulation	Expression	SLC2A1	hsa6513
	Down-regulation	Expression	SLC7A11	hsa23657
In Vitro Model	PaTu 8988s	Pancreatic adenocarcinoma	Homo sapiens (Human)	CVCL_1846
In Vitro Model	BxPC-3	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0186
In Vivo Model	Panc02 cells (1×10⁵ cells/site) were transfected and subcutaneously injected into 4-week-old C57BL/6 mice to generate xenografts.
Result	The combination of erastin and vitamin C exerts a synergistic effect of classical and nonclassical modes to induce ferroptosis in PC cells, which may provide a promising therapeutic strategy for PC.

Pair Name	Luteolin, Erastin
Partner Name	Luteolin
Disease Info	[ICD-11: 2B90]	Colon cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Down-regulation	Expression	GPX4	hsa2879
Gene Regulation	Up-regulation	Expression	HIC1	hsa3090
In Vitro Model	HCT 116	Colon carcinoma	Homo sapiens (Human)	CVCL_0291
In Vitro Model	SW480	Colon adenocarcinoma	Homo sapiens (Human)	CVCL_0546
In Vivo Model	The mice were subjected to subcutaneously injection with HCT116 cells (5×10⁶, suspended in PBS) in each right flank, the mice were treated every 2 days for eight times.
Result	These results clearly demonstrated that luteolin acts synergistically with erastin and renders colon cancer cells vulnerable to ferroptosis through the HIC1-mediated inhibition of GPX4 expression, which may act as a promising therapeutic strategy.

Pair Name	Cucurbitacin B, Erastin
Partner Name	Cucurbitacin B
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Ferroptosis
Gene Regulation	Up-regulation	Expression	IREB2	hsa3658
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Cucurbitacin B and erastin co-treatment synergistically induced ferroptosis in breast cancer cells via altered iron-regulating proteins and lipid peroxidation